MCID: ANG015
MIFTS: 52

Angioedema malady

Categories: Genetic diseases, Skin diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioedema

About this section

Aliases & Descriptions for Angioedema:

Name: Angioedema 11 50 39 13 68
Angioneurotic Oedema 11
Angioneurotic Edema 11
 
Giant Urticaria 11
Quincke's Edema 11

Classifications:



External Ids:

Disease Ontology11 DOID:1558
ICD1030 T78.3
MeSH39 D000799
NCIt45 C112175

Summaries for Angioedema

About this section
Disease Ontology:11 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary: Angioedema, also known as angioneurotic oedema, is related to hereditary angioedema and angioedema induced by ace inhibitors, and has symptoms including edema and joint swelling. An important gene associated with Angioedema is SERPING1 (Serpin Family G Member 1), and among its related pathways are A-beta Pathways: Plaque Formation and APP Metabolism and A-beta Pathways: Uptake and Degradation. The drug fluoxymesterone has been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and endothelial.

Wikipedia:71 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

About this section

Diseases in the Angioedema family:

Angioedema, Hereditary, Type Iii Angioedema, Hereditary, Types I and Ii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 147)
idRelated DiseaseScoreTop Affiliating Genes
1hereditary angioedema12.4
2angioedema induced by ace inhibitors12.3
3angioedema, hereditary, type iii12.2
4angioedema, hereditary, types i and ii12.2
5acquired angioedema12.2
6episodic angioedema with eosinophilia12.2
7acquired angioedema type 211.8
8acquired angioedema type 111.7
9c1 inhibitor deficiency11.7
10vibratory urticaria11.5
11carboxypeptidase n deficiency10.7
12loiasis10.7
13complement component 4, partial deficiency of10.7
14urticaria10.4
15acro coxo mesomelic dysplasia10.2C1S, SERPING1
16lymph node cancer10.1KNG1, SERPING1
17malignant acth producing neoplasm of pituitary gland10.1C1S, KNG1, SERPING1
18secretory diarrhea myopathy and deafness10.1ACE, KNG1
19lymphoma10.0
20laryngitis10.0
21chylocele of tunica vaginalis10.0ACE, KLKB1, KNG1
22petrositis10.0ACE, KLKB1, KNG1
23charcot-marie-tooth disease 2a2b9.9C1S, KNG1, PTGS2, SERPING1
24lupus erythematosus9.9
25critical limb ischemia9.9ACE, KNG1, MME
26microcystic adenoma9.9C1S, MME
27pancreatitis9.8
28systemic lupus erythematosus9.8
29thyroiditis9.8
30endotheliitis9.8
31dermatitis9.8
32acute pancreatitis9.8
33ischemia9.8
34artemis deficiency9.7BDKRB2, C1S, KLKB1, KNG1, SERPING1
35macroglossia9.7
36arthritis9.7
37physical urticaria9.7
38adult-onset still's disease9.7
39contact dermatitis9.7
40fasciitis9.7
41carcinoid syndrome9.7
42leukocyte adhesion deficiency, type iii9.6BDKRB2, C1S, F12, KLKB1, KNG1, SERPING1
43hodgkin lymphoma9.6
44celiac disease9.6
45psoriatic arthritis9.6
46eosinophilic fasciitis9.6
47atherosclerosis9.6
48chronic lymphocytic leukemia9.6
49crohn's disease9.6
50hemolytic anemia9.6

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to angioedema

Symptoms & Phenotypes for Angioedema

About this section

UMLS symptoms related to Angioedema:


edema, joint swelling

Drugs & Therapeutics for Angioedema

About this section

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 194)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Omalizumabapproved, investigationalPhase 4, Phase 3, Phase 2145242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
2
ZincapprovedPhase 422967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
3
LoratadineapprovedPhase 4, Phase 210079794-75-53957
Synonyms:
1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester
1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester
4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
79794-75-5
AC-2086
AC1L1H3E
Aerotina
Alarin
Alavert
Alavert, Claritin, Loratadine
Alerpriv
Allertidin
Amantadine
Anhissen
BB_SC-2109
BIDD:GT0198
BRD-K82795137-001-02-3
BRD-K82795137-001-10-6
BSPBio_002300
Bedix Loratadina
Biloina
Bonalerg
C22H23ClN2O2
CHEMBL998
CID3957
CPD000058255
Children's Claritin
Civeran
Claratyne
Claratyne Cold
Claratyne Decongestant
Clarinase
Clarinase Reperabs
Claritin
Claritin (TN)
Claritin D
Claritin Hives Relief
Claritin Hives Relief Reditab
Claritin Reditabs
Claritin reditab
Claritine
Clarityn
Clarityne
Clarityne Dy Repetabs
Clarityne-D
Clarium
Cronopen
D00364
D017336
DB00455
DivK1c_000792
EU-0100680
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate
Flonidan
Fristamin
HMS2051G11
HMS2090O18
HMS2093I15
HMS502H14
HSDB 3578
Histaloran
I14-0747
IDI1_000792
KBio1_000792
KBio2_001976
KBio2_004544
KBio2_007112
KBio3_001520
KBioGR_000693
KBioSS_001976
Klaritin
L 9664
L000667
L0223
L9664_SIGMA
LS-114660
 
Lergy
Lertamine
Lesidas
Lisino
Lopac-L-9664
Lopac0_000680
Loracert
Loradex
Loradif
Loranox
Lorantis
Lorastine
Loratadina
Loratadina [Spanish]
Loratadine
Loratadine (JAN/USAN/INN)
Loratadine Redidose
Loratadine Wyeth Brand
Loratadine [USAN:BAN:INN]
Loratadinum
Loratadinum [Latin]
Loratidine
Loratyne
Loraver
Lorfast
Loritine
Lowadina
MLS000069647
MLS000758260
MLS001148466
MolPort-002-507-846
NCGC00015619-01
NCGC00015619-02
NCGC00015619-06
NCGC00015619-10
NCGC00023125-02
NCGC00023125-04
NCGC00023125-05
NCGC00023125-06
NCGC00023125-07
NCI60_041473
NINDS_000792
NSC721075
Nularef
Oprea1_027965
Optimin
Polaratyne
Pylor
Restamine
Rhinase
Rinomex
Roletra
S1358_Selleck
SAM001246987
SMR000058255
SPBio_001548
SPECTRUM1503712
STK574925
Sanelor
Sch 29851
Sch-29851
Sch29851
Sensibit
Sinhistan Dy
Sohotin
Spectrum2_001584
Spectrum3_000740
Spectrum4_000177
Spectrum5_001650
Spectrum_001496
TL8005389
Tadine
Talorat Dy
Tocris-1944
UNII-7AJO3BO7QN
Velodan
Versal
Wyeth Brand of Loratadine
ZINC00537931
Zeos
ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate
loratadine
4
Histamineapproved, investigationalPhase 4, Phase 2, Phase 3105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
5
EverolimusapprovedPhase 41940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
6
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7
EnalaprilatapprovedPhase 412476420-72-96917719
Synonyms:
(2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate
1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
76420-72-9
AC1NUWEA
AC1OCEK7
BIDD:GT0752
C11720
C18H24N2O5.2H2O
CHEBI:116759
CHEBI:42302
CHEBI:4786
CHEBI:59877
CHEMBL1200697
CHEMBL577
CID5462501
CID6917719
CPD000466359
D03769
EAL
ENALAPRILAT INHIBITOR
Enalapril acid
Enalapril diacid
Enalaprilat
Enalaprilat (USP)
 
Enalaprilat anhydrous
Enalaprilate
Enalaprilatum
Enalaprilic acid
Enalprilate hydrate
HMS2051H16
HMS2089P04
LS-118903
LS-187219
MK-422
MLS000759476
MLS001424138
MolPort-005-943-792
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline--water (1/2)
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline—water (1/2)
NCGC00164593-01
S1657_Selleck
SAM001246684
SBB065733
SMR000466359
Vasotec I.V.
enalaprilat dihydrate
enalaprilat hydrate
enalprilat hydrate
enalprilate hydrate
8
Enalaprilapproved, vet_approvedPhase 412475847-73-35362032, 40466924
Synonyms:
(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
75847-73-3
AC1NTUS5
Analapril
BIDD:GT0751
BPBio1_000340
BSPBio_000308
BSPBio_003035
Bonuten
C06977
CAS-76095-16-4
CHEBI:116847
CHEBI:4784
CHEMBL578
CID5388962
D07892
DivK1c_000408
Enalapril
Enalapril (INN)
Enalapril (TN)
Enalapril Bp
Enalapril Maleate
Enalapril Richet
Enalaprila
Enalaprila [INN-Spanish]
Enalaprilat
Enalaprilum
 
Enalaprilum [INN-Latin]
Gadopril
HMS2090E08
IDI1_000408
KBio1_000408
KBio2_001787
KBio2_004355
KBio2_006923
KBio3_002535
KBioGR_000355
KBioSS_001787
Kinfil
LS-190651
MolPort-002-885-877
N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline
N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline
NCGC00016932-01
NCGC00021569-04
NCGC00021569-05
NCGC00021569-06
NINDS_000408
Prestwick3_000314
SPBio_001349
Spectrum2_001455
Spectrum3_001478
Spectrum4_000008
Spectrum5_001107
Spectrum_001307
Vaseretic
Vasotec
Vasotec IV
enalapril
9
Sirolimusapproved, investigationalPhase 4194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
10
Desloratadineapproved, investigationalPhase 470100643-71-8124087
Synonyms:
100643-71-8
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
AC-1279
AC1L3XUD
AKOS000280921
Aerius
Allex
Azomyr
BB_SC-2104
C121345
CHEBI:291342
CHEMBL1172
CID124087
CPD000149358
Claramax
Clarinex
Clarinex (TN)
Clarinex RediTabs
Clarinex Reditabs
D03693
D3787
DB00967
DESLORATADINE
Denosin
Desalex
Descarboethoxyloratadine
Descarboethoxyoratidine
 
Desloratadine
Desloratadine (USAN/INN)
Desloratadine [USAN]
Desloratidine
Essex brand of desloratadine
HMS2052H05
HMS2090C06
HMS2093F19
I06-1866
L001025
LS-181814
MLS000559042
MLS000759406
MLS001201801
MolPort-000-883-875
NCGC00159325-02
NCGC00159325-03
NCGC00159325-04
NSC675447
NeoClarityn
Neoclarityn
Opulis
SAM001246545
SMR000149358
STK586537
Sch 34117
Sch-34117
Schering brand of desloratadine
Schering-Plough brand of desloratadine
TL8000065
UNII-FVF865388R
desloratadine
11
RamiprilapprovedPhase 415287333-19-55362129
Synonyms:
(2 S ,3 aS ,6 aS )-1[( S )-N-[( S )-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name)
(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid.
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic
(2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p
(2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
126613-39-6
87333-19-5
AC-1347
AC1NSFPR
Acovil
Almirall Brand of Ramipril
Altace
Altace (TN)
Altace (tn)
Astra Brand of Ramipril
AstraZeneca Brand of Ramipril
Aventis Brand of Ramipril
Aventis Pharma Brand of Ramipril
BIDD:GT0803
BSPBio_003347
Bio-0651
C23H32N2O5
CHEBI:289203
CHEBI:8774
CHEMBL1168
CID5362129
CPD000466386
Carasel
Cardace
D00421
D017257
DB00178
Delix
HMS2051E04
HMS2090L11
HMS2093M10
HOE 498
HOE498
Hoe-498
Hoechst Brand of Ramipril
 
Hypren
Hytren
KBio2_002504
KBio2_005072
KBio2_007640
KBio3_002849
KBioGR_001858
KBioSS_002512
LS-58199
Lostapres
MLS000759523
MLS001216547
MLS001423965
MolPort-001-736-571
Monarch Brand of Ramipril
N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid
NCGC00178127-01
Naprix
Pramace
Pramace (discontinued)
Promed Brand of Ramipril
Quark
R0404_SIGMA
Ramace
Ramipril
Ramipril (USP/INN)
Ramipril [USAN:INN:BAN]
Ramiprilum
Ramiprilum [Latin]
Ramipro, Tritace, Altace, Prilace, Ramipril
S1793_Selleck
SAM001246757
SAM002699899
SMR000466386
SPECTRUM1505214
STK801937
Spectrum3_001794
Spectrum4_001269
Spectrum5_001721
Spectrum_001958
Triatec
Tritace
UNII-L35JN3I7SJ
Unipril
Vesdil
Zabien
[2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
[2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen
ramipril
12
IcatibantapprovedPhase 4, Phase 3, Phase 2, Phase 117138614-30-9, 130308-48-471364
Synonyms:
(2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
(2s)-2-({[(3as,7as)-1-({2-[(2s)-2-{[(2s)-2-({[({(4r)-1-[(1-{2-({(2r)-2-amino-5-[(diaminomethylidene)amino]pentanoyl}amino)-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidin-2-yl)carbonyl]-4-hydroxypyrrolidin-2-yl}carbonyl)amino]acetyl}amino)-3-(thiophen-2-yl)propanoyl]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)octahydro-1h-indol-2-yl]carbonyl}amino)-5-[(diaminomethylidene)amino]pentanoic acid(non-preferred name)
130308-48-4
138614-30-9 (acetate)
13996-86-6
153322-84-0
AC1L2G0Q
AC1Q5QRX
AR-1A3141
C59H89N19O13S
CHEBI:163731
CHEMBL411169
 
CID71364
D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK
DB06196
Firazyr
HOE 140
HOE140
Hoe-140
Icatibant
Icatibant [INN]
JE049
KST-1A1301
LS-172762
WIN 65365
WIN-65365
13
Valsartanapproved, investigationalPhase 4295137862-53-460846
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
137862-53-4
AC-4543
AC1L1U1M
AC1Q5QIK
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
BRD-K45158365-001-02-3
BSPBio_003501
Bio-0796
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
 
Kalpress
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
LS-161334
Lacer brand of valsartan
MLS000759423
MLS001424088
Miten
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Nisis
Nisis||
Novartis brand of valsartan
Provas
S1894_Selleck
SAM001246581
SMR000466318
SPBio_001260
SPECTRUM1505209
Sanol brand of valsartan
Schwarz brand of valsartan
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Spectrum_001796
TL8000869
Tareg
UNII-80M03YXJ7I
Vals
Valsarran
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
valsartan
walsartan
|Tareg
14Anti-Asthmatic AgentsPhase 4, Phase 3, Phase 23488
15Respiratory System AgentsPhase 4, Phase 3, Phase 24997
16Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2, Phase 1724
17
protease inhibitorsPhase 4, Phase 3, Phase 2, Phase 15471
Synonyms:
 
protease inhibitors
18Anti-Allergic AgentsPhase 4, Phase 3, Phase 21522
19
BradykininPhase 4, Phase 3, Phase 2, Phase 15058-82-2439201
Synonyms:
Callidin I
Kallidin 9
 
Kallidin I
L-Arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-Arginine
L-Bradykinin
20ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16394
21Vasodilator AgentsPhase 4, Phase 3, Phase 2, Phase 13543
22HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 15470
23KininogensPhase 4, Phase 3, Phase 2, Phase 150
24AntibodiesPhase 4, Phase 3, Phase 2, Phase 16394
25Anti-Infective AgentsPhase 4, Phase 3, Phase 122062
26Anti-Bacterial AgentsPhase 4, Phase 311226
27Antibiotics, AntitubercularPhase 4, Phase 37180
28Antihypertensive AgentsPhase 4, Phase 2, Phase 34207
29Antifungal AgentsPhase 4, Phase 13696
30Angiotensin II Type 1 Receptor BlockersPhase 4, Phase 2, Phase 31091
31Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 16501
32LCZ 696Phase 4, Phase 254
33AnalgesicsPhase 4, Phase 3, Phase 2, Phase 111733
34Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110729
35Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
36Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 2, Phase 14443
37
Angiotensin IIPhase 4, Phase 2, Phase 3117868521-88-0, 11128-99-765143, 172198
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
38Angiotensin Receptor AntagonistsPhase 4, Phase 2, Phase 31191
39Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110956
40AngiotensinogenPhase 4, Phase 2, Phase 31177
41Cholinergic AgentsPhase 43992
42Cholinergic AntagonistsPhase 41706
43Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
44Complement System ProteinsPhase 4, Phase 3, Phase 2, Phase 1232
45AntipruriticsPhase 4, Phase 3, Phase 2841
46Complement C1sPhase 4, Phase 3, Phase 2, Phase 132
47Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
48Complement C1 Inactivator ProteinsPhase 4, Phase 3, Phase 2, Phase 151
49Complement C1 Inhibitor ProteinPhase 4, Phase 3, Phase 2, Phase 152
50Histamine AntagonistsPhase 4, Phase 3, Phase 2961

Interventional clinical trials:

(show top 50)    (show all 123)
idNameStatusNCT IDPhase
1A Call Center During HAE Attacks (SOS HAE)CompletedNCT01679912Phase 4
2Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAECompletedNCT01457430Phase 4
3A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZECompletedNCT00914966Phase 4
4Postmarketing Immunogenicity Study in HAE Subjects Treated With BerinertCompletedNCT01467947Phase 4
5Desloratadine 5, 10 and 20mg in Patients With Cold UrticariaCompletedNCT01444196Phase 4
6Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE TreatmentCompletedNCT02550106Phase 4
7Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular SafetyCompletedNCT00359801Phase 4
8Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To SirolimusCompletedNCT00502242Phase 4
9comParIson Of Sacubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure EpisodeRecruitingNCT02554890Phase 4
10Treatment of Idiopathic Angioedema With Xolair as Add-on TherapyNot yet recruitingNCT02966314Phase 4
11Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated AngioedemaTerminatedNCT01574248Phase 4
12C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) ExacerbationWithdrawnNCT01151735Phase 4
13C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) AngioedemaCompletedNCT00125151Phase 3
14C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) AngioedemaCompletedNCT00125541Phase 2, Phase 3
15A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT01912456Phase 3
16Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to TherapyCompletedNCT01723072Phase 3
17Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary AngioedemaCompletedNCT02052141Phase 3
18Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00438815Phase 3
19Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaCompletedNCT01919801Phase 3
20Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedNCT00097695Phase 3
21Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAECompletedNCT02586805Phase 3
22A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)CompletedNCT00912093Phase 3
23Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)CompletedNCT00456508Phase 3
24Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00462709Phase 3
25Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00457015Phase 3
26Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00225147Phase 2, Phase 3
27Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262301Phase 3
2812-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksCompletedNCT02303626Phase 2, Phase 3
29Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00500656Phase 3
30Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262288Phase 2, Phase 3
31C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CompletedNCT00292981Phase 3
32C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT01005888Phase 3
33Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00262080Phase 3
34Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksCompletedNCT01188564Phase 3
35Berinert P Study of Subcutaneous Versus Intravenous AdministrationCompletedNCT00748202Phase 3
36EASSI - Evaluation of the Safety of Self-Administration With IcatibantCompletedNCT00997204Phase 3
37Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCompletedNCT00168103Phase 2, Phase 3
38C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00289211Phase 3
39AVE7688 in Patients With Mild to Moderate Blood PressureCompletedNCT00284128Phase 2, Phase 3
40OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) PatientsCompletedNCT02161562Phase 3
41Bilastine Updosing in Chronic Spontaneous UrticariaCompletedNCT02213367Phase 3
42Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in EmergencyCompletedNCT02565680Phase 2, Phase 3
43A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)CompletedNCT01292473Phase 3
44A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedNCT01287117Phase 3
45A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor AntagonistsCompletedNCT01264939Phase 3
46Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced AngioedemaRecruitingNCT01843530Phase 3
47Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus InfectionRecruitingNCT02365493Phase 3
48Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAEActive, not recruitingNCT02741596Phase 3
49A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaActive, not recruitingNCT01386658Phase 3
50Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaActive, not recruitingNCT02584959Phase 3

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

About this section

Anatomical Context for Angioedema

About this section

MalaCards organs/tissues related to Angioedema:

36
Skin, Tongue, Endothelial, Thyroid, B cells, Testes, Heart

Publications for Angioedema

About this section

Articles related to Angioedema:

(show top 50)    (show all 1274)
idTitleAuthorsYear
1
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV. (28073873)
2017
2
Clinical characteristics in cholinergic urticaria with palpebral angioedema: Report of 15 cases. (27876252)
2017
3
Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). (27905115)
2017
4
Manifestations of hereditary angioedema. (28007084)
2017
5
A Case of Miller Fisher Syndrome, Thromboembolic Disease, and Angioedema: Association or Coincidence? (28090073)
2017
6
Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency. (28069032)
2017
7
A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation. (27826968)
2017
8
Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. (27865714)
2017
9
Current and future therapies for the treatment of histamine-induced angioedema. (28081650)
2017
10
Computational Modeling of Tracheal Angioedema due to Swelling of the Submucous Tissue Layer. (28052555)
2017
11
Complements Are Not Always a Good Thing: Novel Therapies for Angioedema. (27139131)
2016
12
Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. (27931305)
2016
13
Prophylactic treatment with plasma-derived C1-inhibitor in idiopathic non-histaminergic angioedema. (27145263)
2016
14
Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema. (27017557)
2016
15
Racecadotril + ACE inhibitors: angioedema. (27213193)
2016
16
Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema. (26959713)
2016
17
Orolingual angioedema to alteplase. Identify, counsel and monitor at risk patients. (27591036)
2016
18
Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. (27911016)
2016
19
How we manage persons with hereditary angioedema. (27071490)
2016
20
Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. (26969268)
2016
21
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency. (27940765)
2016
22
The isolated human umbilical vein as a bioassay for kinin-generating proteases: an in vitro model for therapeutic angioedema agents. (27165535)
2016
23
It's Not Always What It Seems: Necrotizing Fasciitis Mimicking Angioedema. (27072731)
2016
24
A Female with Hereditary Angioedema Developing Wheals: A Case Report. (27350434)
2016
25
Noscapine: angioedema. (27213192)
2016
26
Atrial natriuretic peptide as a novel biomarker of hereditary angioedema. (26960949)
2016
27
Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. (27913306)
2016
28
Ofloxacin Induced Angioedema: A Rare Adverse Drug Reaction. (28050397)
2016
29
Tamoxifen may cause life-threatening angioedema attacks in patients with hereditary angioedema. (27878882)
2016
30
First report of icatibant treatment in a pregnant patient with hereditary angioedema. (27093898)
2016
31
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration. (27174372)
2016
32
Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema. (27660419)
2016
33
Diagnostic utility of challenge procedures for physical urticaria/angioedema syndromes: a systematic review. (27585061)
2016
34
Hereditary angioedema: A rare cause of pancreatitis. (27576199)
2016
35
Hereditary Angioedema: Death after a Dental Extraction. (27491932)
2016
36
A case of acquired angioedema possibly associated with adenocarcinoma of the colon. (27026513)
2016
37
C1-esterase inhibitor for short-term prophylaxis in a patient with hereditary angioedema with normal C1 inhibitor function. (27871580)
2016
38
International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. (27503784)
2016
39
Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema. (27463190)
2016
40
Carbamazepine-induced angioedema. (27999472)
2016
41
Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance. (27660422)
2016
42
Acute Angioedema in a Patient Who Received Ketamine and Succinylcholine: A Case Report. (27625106)
2016
43
Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor. (27788880)
2016
44
New mutations in SERPING1 gene of Brazilian patients with hereditary angioedema. (26812872)
2016
45
Genetics of Hereditary Angioedema Revisited. (27116602)
2016
46
Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema. (28025012)
2016
47
Hereditary angioedema with F12 mutation: Clinical features and enzyme polymorphisms in 9 Southwestern Spanish families. (27788882)
2016
48
Drug-induced non-immune-mediated angioedema. (27152403)
2016
49
High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. (27686124)
2016
50
Efficacy of Omalizumab in a Patient with Angioedema Clinically Resembling a Hereditary Angioedema. (27274639)
2016

Variations for Angioedema

About this section

Expression for genes affiliated with Angioedema

About this section
Search GEO for disease gene expression data for Angioedema.

Pathways for genes affiliated with Angioedema

About this section

Pathways related to Angioedema according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.7ACE, MME
29.7ACE, MME
39.5LTC4S, PTGS2
49.4F12, KLKB1
59.1F12, KLKB1, SERPING1
6
Show member pathways
9.1ACE, DPP4, MME
7
Show member pathways
9.0ACE, BDKRB2, KNG1, MME
8
Show member pathways
8.8F12, KLKB1, KNG1, SERPING1
9
Show member pathways
8.1BDKRB2, C1S, F12, KLKB1, KNG1, SERPING1
10
Show member pathways
7.5DPP4, F12, KLKB1, KNG1, MME, XPNPEP2

GO Terms for genes affiliated with Angioedema

About this section

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1blood microparticleGO:007256210.4C1S, KNG1, SERPING1
2extracellular exosomeGO:00700627.3ACE, C1S, DPP4, F12, KLKB1, KNG1
3extracellular regionGO:00055767.0ACE, C1S, DPP4, F12, KLKB1, KNG1

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1blood circulationGO:000801510.6BDKRB2, SERPING1
2arachidonic acid secretionGO:005048210.5ACE, BDKRB2
3angiotensin maturationGO:000200310.4ACE, MME
4beta-amyloid metabolic processGO:005043510.4ACE, MME
5negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressGO:190221910.3BDKRB2, PTGS2
6lipoxygenase pathwayGO:001937210.2LTC4S, PTGS2
7regulation of vasoconstrictionGO:001922910.2ACE, BDKRB2
8Factor XII activationGO:000254210.1F12, KLKB1
9positive regulation of fibrinolysisGO:005191910.1F12, KLKB1
10vasodilationGO:004231110.0BDKRB2, KNG1
11fibrinolysisGO:00427309.8F12, KLKB1, SERPING1
12blood coagulationGO:00075969.5F12, KLKB1, KNG1, SERPING1
13blood coagulation, intrinsic pathwayGO:00075979.5F12, KLKB1, KNG1, SERPING1
14hemostasisGO:00075999.5F12, KLKB1, KNG1, SERPING1
15zymogen activationGO:00316389.4F12, KLKB1
16inflammatory responseGO:00069549.2BDKRB2, KLKB1, KNG1, PTGS2
17proteolysisGO:00065087.6ACE, C1S, DPP4, F12, KLKB1, MME

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1exopeptidase activityGO:000823810.5ACE, MME
2aminopeptidase activityGO:000417710.1DPP4, XPNPEP2
3metallopeptidase activityGO:00082379.9ACE, MME, XPNPEP2
4serine-type endopeptidase activityGO:00042529.0C1S, DPP4, F12, KLKB1
5serine-type peptidase activityGO:00082368.4C1S, DPP4, F12, KLKB1
6hydrolase activityGO:00167877.9ACE, C1S, DPP4, F12, KLKB1, MME
7peptidase activityGO:00082337.8ACE, C1S, DPP4, F12, KLKB1, MME

Sources for Angioedema

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet